Core Insights - The article highlights the recent announcement of 61 procurement intentions for scientific instruments, with a total budget of 421 million yuan, expected to be executed between March and June 2026 [1][2]. Procurement Overview - The procurement list includes various advanced scientific instruments such as: - Triple quadrupole mass spectrometers - High-resolution mass spectrometers - Time-of-flight mass spectrometry ion mobility modules - High-frequency photodetectors - The total budget for these instruments is 421 million yuan [2][3]. Detailed Procurement List - Specific projects and their budgets include: - Zhuque Flight Laboratory Phase II: 19 million yuan, scheduled for June 2026 [3]. - Time-of-flight mass spectrometry ion mobility module: 6 million yuan, scheduled for June 2026 [4]. - Triple quadrupole mass spectrometer: 3 million yuan, scheduled for June 2026 [5]. - High-resolution mass spectrometer: 6.5 million yuan, scheduled for June 2026 [8]. - Biological sample collection and processing stations: 12.48 million yuan, scheduled for June 2026 [8]. - Infection sample and data management workstation: 14 million yuan, scheduled for June 2026 [8]. Instrument Specifications - The instruments are designed to enhance efficiency and reliability in pathogen detection and analysis, with features such as: - High automation and standardized processes to improve detection efficiency and result reliability [3][4]. - Specific dimensions and operational requirements for mobile and field applications [4]. - Advanced capabilities for analyzing complex biological samples and supporting large-scale clinical research [8][9]. Conclusion - The procurement intentions reflect a significant investment in scientific research infrastructure, aiming to enhance capabilities in pathogen detection, biological analysis, and data management, which are critical for advancing public health and scientific research [1][2].

Core Viewpoint - The beauty industry is currently facing a significant controversy regarding the actual content of recombinant collagen, with a focus on the lack of standardized testing methods and criteria, which has led to a trust gap between brands and consumers [2]. Group 1: Industry Controversy - A beauty blogger reported that the recombinant collagen content in a popular product was only 0.0177%, significantly below the national standard of 0.1%, and failed to detect key amino acids like glycine [2]. - The controversy centers not on the technical routes or raw material sources, but on the choice of testing methods and the absence of unified standards, which has hindered the compliant development of the medical beauty industry [2]. Group 2: Regulatory Developments - Since 2022, the National Medical Products Administration (NMPA) has been releasing industry standards for recombinant collagen, including YY/T 1849-2022 and YY/T 1888-2023, to address the heterogeneity of recombinant collagen products [3]. - The introduction of mass spectrometry as a "gold standard" for quality control in recombinant collagen is expected to replace traditional methods that are susceptible to interference from other proteins [3]. Group 3: New Standards Implementation - On August 1, 2022, the NMPA implemented YY/T 1805.3-2022, which provides a high-specificity method for detecting collagen content using LC-MS/MS, addressing the limitations of traditional methods [4]. - A new standard, YY/T 1954-2025, for peptide fingerprint analysis of recombinant collagen is set to be implemented on March 1, 2026, which will enhance quality control and regulatory capabilities in the medical beauty industry [8]. Group 4: Industry Support and Collaboration - The Instrument Information Network is actively monitoring developments in cosmetic testing and promoting collaboration in the field, emphasizing the importance of advancements in testing technology and equipment [13].